Garth Strohbehn, M.D., M.Phil.

Dr. Strohbehn’s research focuses on the impact of drug dosing on patient safety, treatment access, and healthcare costs. He is particularly interested in the development of clinical trials investigating lower intensity, less frequent, and shorter duration therapies that maximize benefits, specifically for cancer patients. Dr. Strohbehn’s work aims to shift policy toward safer, less costly treatment practices locally and globally. 

• M.D., Yale School of Medicine
• M.Phil., Clinical Biochemistry, Cambridge University
• B.A., Chemistry, University of Iowa
• B.S., Biochemistry, University of Iowa